Your browser doesn't support javascript.
loading
Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors.
Ohkuma, Ryotaro; Miura, Sakiko; Muto, Satoshi; Toyomasu, Yoshitaka; Fujimoto, Yuki; Ieguchi, Katsuaki; Onishi, Nobuyuki; Shimizu, Takashi; Watanabe, Makoto; Takayanagi, Daisuke; Goshima, Tsubasa; Horiike, Atsushi; Hamada, Kazuyuki; Ariizumi, Hirotsugu; Shimokawa, Masahiro; Hirasawa, Yuya; Ishiguro, Tomoyuki; Suzuki, Risako; Iriguchi, Nana; Tsurui, Toshiaki; Mura, Emiko; Takenoshita, Sachiko; Numajiri, Kazuki; Okabe, Naoyuki; Yoshimura, Kiyoshi; Tsuji, Mayumi; Kiuchi, Yuji; Yajima, Toshiki; Ishida, Hideyuki; Suzuki, Hiroyuki; Yamochi, Toshiko; Kobayashi, Shinichi; Tsunoda, Takuya; Wada, Satoshi.
Afiliación
  • Ohkuma R; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
  • Miura S; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Muto S; Department of Pathology, Showa University School of Medicine, Tokyo, Japan.
  • Toyomasu Y; Department of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, Japan.
  • Fujimoto Y; Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
  • Ieguchi K; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
  • Onishi N; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Shimizu T; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Watanabe M; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Takayanagi D; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Goshima T; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Horiike A; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Hamada K; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Ariizumi H; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Shimokawa M; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Hirasawa Y; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Ishiguro T; Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.
  • Suzuki R; Pharmacological Research Center, Showa University, Tokyo, Japan.
  • Iriguchi N; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
  • Tsurui T; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Mura E; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Takenoshita S; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
  • Numajiri K; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Okabe N; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Yoshimura K; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
  • Tsuji M; Department of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, Japan.
  • Kiuchi Y; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
  • Yajima T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
  • Ishida H; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
  • Suzuki H; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
  • Yamochi T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
  • Kobayashi S; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
  • Tsunoda T; Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
  • Wada S; Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.
Front Immunol ; 14: 1260492, 2023.
Article en En | MEDLINE | ID: mdl-37790929
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pulmonares Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pulmonares Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Japón